Pevonedistat

Leukemia, Myelomonocytic, Chronic

TakedaPhase 3Active

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 95/ 100

Competitive context

97 Active assets in the Leukemia, Myelomonocytic, Chronic cohort.

Asset / Sponsor	Phase	Rating
Venetoclax Servier Bio-Innovation LLC	Phase 2/3	BB
CYCLOSPORIN A Fred Hutchinson Cancer Center	Phase 2	BB
Astx727 Taiho Oncology, Inc.	Phase 3	BB
Evomela City of Hope Medical Center	Phase 2	BB
Idarubicine Fred Hutchinson Cancer Center	Phase 3	BB

View all 50 →

Same molecule, other indications

Pevonedistat is also rated in:

acute myeloid leukemiaDormant

BB

Indicative ·

66 / 100

myelodysplastic syndromeDormant

B

Indicative ·

60 / 100

Therapy-Related Acute Myeloid LeukemiaDormant

B

Indicative ·

56 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.